Who is the sponsor?
Genentech, Inc.
Who are the patients?
Male or female 55 years of age and older with geographic atrophy due to dry age-related macular degeneration. The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.
How long is the trial?
Approximately 21 months.
What is the enrollment goal for the sponsor?
Enrollment was completed in June 2011. 120 patients were enrolled into this study.
What is this study investigating?
This is a Phase 1, multi-center, short-term study to test the safety of a new experimental drug in patients with geographic atrophy. This study will explore the effects of the drug in the eye and in the body, if any. Participants will undergo complete ophthalmic evaluation and undergo blood and urine analysis. Results from this short-term study will be used to support a larger long-term, multi-center clinical trial to test the effectiveness of the compound.
How is the treatment administered?
Participants will be randomized to receive intravitreal eye injections of study drug monthly or every other month or sham injections monthly or every other month.